Zandatrigine

DB19051InvestigationalSmall molecule

Zandatrigine is under investigation in clinical trial NCT05226780 (Extension Study to Evaluate How Safe and Tolerable NBI-921352 Is as an Adjunctive Therapy for Participants With SCN8A-DEE).

Mechanism: Pharmacologically active on Sodium channel protein type 8 subunit alpha
Curator reviewed
Formula / weight: C₂₂H₂₅FN₄O₂S₂ · 460.59 g/mol (avg)
Also known as: Benzenesulfonamide, 2-fluoro-5-methyl-4-(methyl((3s)-1-(phenylmethyl)-3-pyrrolidinyl)amino)-n-4-thiazolyl-
Code names: NBI-921352 · XEN-901

Resolves to

Compound

UNIISV2WPA4R4JCAS2154406-04-7ChEMBLCHEMBL4650313

Structure

InChIKeyUCSHINHOAVARGQ-SFHVURJKSA-NSMILESCN([C@H]1CCN(CC2=CC=CC=C2)C1)C1=CC(F)=C(C=C1C)S(=O)(=O)NC1=CSC=N1

Targets

Q9UQD0SCN8A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zandatrigine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account